CCI-779: Wyeth

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1249-1253

  Elit, Laurie ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; FUNGICIDE; MACROLIDE; PROTEIN SYNTHESIS INHIBITOR; RAPAMYCIN; TAXANE DERIVATIVE; TEMSIROLIMUS;

ACUTE ABDOMEN; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST TUMOR; CLINICAL TRIAL; DEHYDRATION; DERMATITIS; DIGESTIVE SYSTEM PERFORATION; DISORDERS OF HORMONE METABOLISM; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; FATIGUE; FOLLICULITIS; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; KIDNEY TUMOR; LEUKOPENIA; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; NAIL DISEASE; NONHUMAN; PRURITUS; REVIEW; SKIN TOXICITY; SKIN ULCER; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; NEOPLASMS; PROTEIN SYNTHESIS INHIBITORS; SIROLIMUS;

EID: 0036707338     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. 320924 American Association for Cancer Research - 90th Annual Meeting (Part II), Philadelphia, PA, USA. Robins P IDDB Meeting Report 1999 April 10-14
2. 322087 The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Gibbons JJ, Discafani C, Peterson R, Hernandez R, Skotnicki J, Frost P Proc Am Assoc Cancer Res 40 Abs 2000
3. 326102 Rapamycin analog CCI-779 inhibits growth of human medulloblastoma xenografts. Geoerger B, Kerr K, Janss AJ, Sutton LN, Phillips PC Proc Annu Meet Am Assoc Cancer Res 1999 40 Abs 3978
4. 362692 Phase I study of CCI-779, A novel rapamycin analog: Preliminary results. Alexandre J, Raymond E, Depenbrock H, Mekhaldi S, Angevin E, Paillet C, Hanauske A, Le Chevalier T, Escudier B, Frisch J, Feussner A, Armand JP Proc Annu Meet Am Assoc Cancer Res 2000 41 Abs 3897
5. 369509 CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study. Hidalgo M, Rowinsky E, Erlichman C, Drengler R, Marshall B, Adjei A, Hammond L, Speicher L, Galanis E, Edwards T, Boni J et al Proc Am Soc Clin Oncol 2000 19 Abs 726
6. 369515 CCI-779, a rapamycin analog with antitumor activity: A phase I study utilizing a weekly schedule. Raymond E, Alexandre J, Depenbrock H, Mekhaldi S, Angevin E, Hanauske A, Baudin E, Escudier B, Frisch J, Boni J, Armand JP Proc Am Soc Clin Oncol 2000 19 Abs 728
7. 391070 Phase 1 and pharmacological study of CCI-779, a cell cycle inhibitor. Hidalgo M, Rowinsky E, Erlichman C, Drengler R et al NCI EORTC Symp New Drug Cancer Ther 2000 11 Abs 413
8. 391088 CCI-779, an ester analogue of rapamycin that interacts with PTEN/P13 kinase pathways: A phase 1 study utilizing a weekly intravenous schedule. Raymond E, Alexandre J, Depenbrock H, Ady Vago N, Faivre S et al NCI EORTC Symp New Drugs Cancer Ther 2000 11 Abs 414
9. 405206 Deregulation P13k/AKT/TOR pathway in PTEN-deficient tumour cells correlates with an increased growth inhibition sensitivity to a TOR kinase inhibitor CCI-779. Yu K, Zhang W, Lucas J, Toral Barza L, Peterson R, Skotnicki J, Frost P, Gibbons J Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 4305
10. 418901 American Home Products sales model. Lehman Brothers Inc 2001 June 19
11. 420809 Pharmaceutical desk reference: Global equities research US - Our models of the major US pharma companies. Lehman Brothers Inc 2001 August
12. 426718 Equity research, pharmaceuticals: Company comment - American Home Products. Krensavage M, Bailey M Raymond James & Associates Inc 2001 October 1
13. 428972 CIBC World Markets Health Care Conference. American Home Products Corp Company Presentation 2001 November 06
14. 429576 Molecular targets and cancer therapeutics - AACR-NCI-EORTC International Conference (Part I), Discovery, Biology, and Clinical Applications, Miami Beach, FL, USA. D'Incalci M, Damia G IDDB Meeting Report 2001 October 29 - November 2
15. 430367 Mammalian target of rapamycin (mTOR) as a target for cancer therapeutic development. Dancy J AACR NCI EORTC Mol Targets Cancer Ther 2001 Abs W830
16. 430946 A phase I study of escalating doses of CCI-779 in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Punt CJA, Bruntsch U, Hanauske AR, Weigang Koehler K, Peters M, Thielert C, Frisch J Eur J Cancer 37 Suppl 6 2001 Abs 53
17. 431231 Pharmacokinetics of escalating doses of CCI-779 in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Boni J, Korth-Bradley J, Punt CJA, Hanauske A, Weigang Koehler K, Thielert C, Frisch J Eur J Cancer 37 Suppl 6 2001 Abs 242
18. 432917 Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: The identification of CCI-779. Skotinicki JS, Leone CL, Smith AL, Palmer YL, Yu K, Discafani CM, Gibbons JJ, Frost P, Abou Gharbia MA AACR NCI EORTC Mol Targets Cancer Ther 2001 Abs 477
19. 436554 Cell cycle regulation in the G1 phase: A promising target for the development of new chemotherapeutic anticancer agents. Owa T, Yoshino H, Yoshimatsu K, Nagasu T Curr Med Chem 2001 8 12 1487-1503 Detailed overview on cell cycle regulation in the G1 phase.
20. 439022 mTOR, anovel target in breastcancer: The effect of CCi-779, an mTOR inhibitor, preclinical models of breast cancer. Yu K, Toral Barza L, Discafani C, Skotnicki J, Frost P, Gibbons JJ Endocr-Relat Cancer 2001 8 3 249-258
21. 439026 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL Proc Natl Acad Sci USA 2001 98 18 10314-10319
22. 439027 An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/- mice. Podsypania K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P et al Proc Natl Acad Sci USA 2001 98 18 10320-10325
23. 439028 The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Hidalgo M, Rowinsky EK Oncogene 2000 19 56 6680-6686 Excellent comprehensive review article on the development of CCI-779.
24. 439029 Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Dudkin L, Diling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ Clin Cancer Res 7 6 1758-1764 Role of 4E-BP1 assay in determining CCI-779 use.
25. 439030 Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ Cancer Res 2001 61 4 1527-1532 Excellent review of CCI-779 and neuroectoderm models.
26. 439031 Rapamcyin and CCI-779. Alexandre J, Raymond E, Armand JP Bull Cancer 86 10 808-811
27. 441265 Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. Curr Opin Invest Drugs 2002 3 295-304
28. 442535 FDA designates Wyeth-Ayerst's investigational treatment for renal cell carcinoma for fast-track development. Wyeth-Ayerst Laboratories Press Release 2002 March 06
29. 443491 Presentations: SG Cowen Health Care Conference - March 12, 2002. Wyeth Company Presentation 2002 March 12
30. 444030 Annual report 2001: Wyeth. Wyeth Annual Report 2002 March 14
31. 446642 PTEN expression status predict glioblastoma cell sensitivity to CCI-779. Smith SG, Trinh CN, Inge LJ, Thomas G, Cloughsey TF, Sawyers CL, Mischel PS Proc Annu Meet Am Assoc Cancer Res 2002 43 Abs 1661
32. 447493 Pharmacodynamic evaluation of the rapamycin ester CCI-779. Peralba JM, De Graffenried L, Fulcher L, Silva J, Weiss G, Hidalgo M Proc Annu Meet Am Assoc Cancer Res 43 2002 Abs 4961
33. 451781 American Society of Clinical Oncology - 38th Annual Meeting (Part VI) - Overnight report, Orlando, FL, USA. Erlich R IDDB Meeting Report May 18-21
34. 452502 First report: A phase II study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Chan S, Johnston S, Scheulen ME, Mross K, Morant R, Lahr A, Feussner A, Berger M, Kirsch T Proc Am Soc Clin Oncol 2001 21 1 Abs 175
35. 452532 A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Atkins MB, Hidalgo M, Stadler W, Logan T, Dutcher JP, Hudes G, Park Y, Marshall B, Boni J, Dukart G Proc Am Soc Clin Oncol 2002 21 1 Abs 36
36. 453762 Rapamycin's resurrection: A new way to target the cancer cell cycle. Garber K J Natl Cancer Inst 2001 93 20 1517-1519
37. 453821 Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the p13K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Mills GB, Lu Y, Kohn EC Proc Natl Acad Sci USA 2001 98 18 10031-10033
38. 459825 TOR, a central controller of cell growth. Schmelzle T, Hall MN Cell 2000 103 2 253-262 Excellent review showing mTOR as a central regulator of cell growth events, including translation initiation, actin organization, membrane traffic and protein degradation, protein kinase C signaling, ribosome biogenesis and tRNA synthesis, as well as transcription.